Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582290 | 0.92 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL2418189 | 0.85 | ESR2 (0.75) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL2419390 | 0.84 | ESR2 (0.74) | ESR1ESR2 | |
| SCHEMBL2422287 | 0.84 | ESR2 (0.74) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL2418710 | 0.83 | ESR2 (0.73) | ESR1ESR2 | |
| SCHEMBL2424862 | 0.82 | ESR2 (0.70) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL2415542 | 0.81 | ESR2 (0.69) | ESR1ESR2 | |
| SCHEMBL5582427 | 0.81 | ESR1 (0.68) | ESR1ESR2 | |
| SCHEMBL2423713 | 0.78 | ESR2 (0.76) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL2417896 | 0.77 | ESR2 (0.75) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435320-B2 | CRISPR having or associated with destabilization domains | THE BROAD INSTITUTE, INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-12421507-B2 | Methods and compositions for optochemical control of CRISPR-CAS9 | THE BROAD INSTITUTE, INC. (US) | 2025-09-23 | — | — | US | claimed |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | claimed |
| US-20250074959-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2025-03-06 | — | — | US | claimed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | claimed |
| CN-110291200-B | Agent ligand induction of transgene expression in mammalian cells | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-05-14 | — | — | CN | claimed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | claimed |
| EP-4341283-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | claimed |
| EP-3551197-B1 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-11-22 | — | — | EP | claimed |
| CN-116301140-A | Reference current source | 中国科学技术大学 | 2023-06-23 | — | — | CN | claimed |
| US-20220411805-A1 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2022-12-29 | — | — | US | claimed |
| WO-2022241289-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2022174035-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-08-18 | — | — | WO | claimed |
| US-11408005-B2 | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells | SEATTLE CHILDREN'S HOSPITAL (US) | 2022-08-09 | — | — | US | claimed |
| US-20220184217-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2022-06-16 | — | — | US | claimed |
| EP-4003332-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-01 | — | — | EP | claimed |
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | claimed |
| EP-3946320-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | MDM2, TP53, BRCA1 | ESR1 1606/4885ESR2 2493/4885 |
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | SULT1A1, SULT2A1, SULT1E1 | ESR1 2324/4885ESR2 1604/4885 |
| US-20220184217-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | ESR1 3369/4885ESR2 2816/4885 |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | IAPP, ZFR, ZC3H11A | ESR1 1489/4885ESR2 2128/4885 |
| US-12421507-B2 | Methods and compositions for optochemical control of CRISPR-CAS9 | DCLRE1B, DNASE1, ZFR | ESR1 1376/4885ESR2 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.